The Pharmaceutical and Chemical Journal, 2021, 8(6):13-17

Available online www.tpcj.org

Review Article

ISSN: 2349-7092
CODEN(USA): PCJHBA

Role of Rivaroxaban and Aspirin in the Prevention of Cardiac Complications of Covid-19 with Early Acute Coronary Syndrome Therapy

Rajat Singh, Monika Maheshwari*

Geetanjali Institute of Pharmacy, Geetanjali University, Udaipur-313001, Rajasthan, India

Abstract The coronavirus disease 2019 (COVID-19) pandemic due to severe acute respiratory syndrome coronavirus has challenged health-care systems and physicians worldwide to aim to produce the most effective care to their patients with an evolving understanding of this distinctive infective agent. Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. This article aimed to evaluate the efficacy and safety of aspirin in patients with COVID-19. This illness and its worldwide impact have sparked tremendous interest within the medical specialty, pathologic process, and clinical consequences of COVID-19. Our goal is to produce steerage to the employment of antithrombotic and antiplatelet therapies in patients with far-famed or suspected COVID-19.This accumulating body of proof has targeted around case series and sometimes empiric therapies as controlled trials are simply obtaining afoot. What's clear is that patients seem to be at higher risk for thrombotic illness states together with acute coronary syndrome (ACS), blood vessel occlusion (VTE) like deep vein occlusion (DVT) or embolism (PE), or stroke. Patients with underlying disorder also are at higher risk for morbidity and mortality if infected. These patients are normally treated with medical aid and/or antiplatelet medications and fewer normally lysis throughout hospitalization, probably with profit however the management of those medications is troublesome in probably critically sick patients. This article may be acquired to get overview of antithrombotic and NSAIDS in treatment of Covid-19.

Keywords Covid-19, Acute coronary syndrome, rivaroxaban, aspirin, anticoagulant, Antiplatelet

Introduction

Coronavirus 2019 (COVID-19) because of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a international pandemic with over 4.3 million confirmed cases worldwide and over 297,000 deaths as of 15 could 2020. Currently, the United States leads all countries with over 1.3 million confirmed cases and over 82,000 deaths. Illness severity ranges from well to critical illness leading to fatality. Early studies discovered a raised prevalence of acute cardiovascular events resulting in the next risk of mortality. COVID-19 patients could present with hemodynamic instability and raised biomarkers of cardiac injury, specifically troponin and B-Type symptom peptide. This might be due to an acute coronary syndrome (ACS), carditis, and kind a pair of infarction, coronary vasospasm, or stress-induced heart condition. The specificity of those biomarkers during this setting is uncertain. To boot, markedly elevated D-dimer levels are related to severe ill health and high mortality. This has been postulated to be due to small occlusion. Patients conjointly seem at higher risk of venous thromboembolism (VTE) due to critical illness, immobility, and inflammation [1].

Anti-platelet therapy might need useful effects in severe COVID-19 through many mechanisms, together with inhibition of platelet aggregation, reduction of platelet-derived inflammation, and interference of thrombogenic

neutrophil extracellular traps. Aspirin is a reasonable, globally on the market drug that at low doses irreversibly inhibits the cyclooxygenase-1 enzyme, that is answerable for production of thromboxane A2 and proinflammatory prostaglandins. Aspirin will reduce each blood vessel and venous thrombotic events and has been shown to stop in-vitro disorder in platelets from patients with SARS-CoV-2., seven Existing evidence from irregular trials has shown that 75–150 mg aspirin per day is as effective as higher doses in preventing cardiovascular events [2]

Seven clinical trials of aspirin in COVID-19 are registered, but none have yet reported on the effect of aspirin therapy in COVID-19. Here it reports the results of a large randomised controlled trial of aspirin in patients hospitalised with COVID-19.

Managing patient's acute antiplatelet and medicine regimens is difficult without clear accord on identification and treatment. Several patients are on antiplatelet and anticoagulants for pre-existent conditions when they present to the hospital and so the balance of any ischemic/thrombotic events vs. haemorrhage events should be weighed. The margin of error seems to be narrower in patients with multi-system failure wherever unsteady organ operate will impact drug metabolism [3-4].



Figure 1: Need for therapeutic anticoagulation [2]

COVID-19 outpatients receiving warfarin who are in isolation and thus unable to have international normalized ratio monitoring may be candidates for switching to direct oral anticoagulant therapy. Patients receiving warfarin who have a mechanical heart valve, ventricular assist device, valvular atrial fibrillation, or antiphospholipid antibody syndrome or who are lactating should continue treatment with warfarin **(AIII)**. Hospitalized patients with COVID-19 who are taking anticoagulant or antiplatelet therapy for underlying medical conditions should continue this treatment unless significant bleeding develops, or other contraindications are present **(AIII)** [5].

It aim to produce guidance for the management of various clinical situations encountered in COVID-19 infected patients recognizing that these recommendations could amendment given the rapidly evolving understanding of COVID-19 pathophysiology.

Acute coronary syndrome (ACS)

The identification of ACS within the COVID-19 patient can be challenging as long as patients often have elevated troponin levels. Biomarkers are nonspecific measures of viscus injury and should represent a myriad of viscus conditions together with heart muscle ischaemia secondary to either plaque rupture or demand ischaemia, carditis, stress cardiomyopathy, or coronary spasm. So as to help with identification and treatment, it's necessary to require into consideration the patient's clinical presentation, electrocardiogram (ECG), and purpose of care ultrasound to evaluate bodily cavity wall motion. Typically, with ACS there's a characteristic rise and fall in troponins that represents heart muscle tissue necrosis due to hypoperfusion, as against carditis which might usually result in elevated however comparatively stable troponin levels that represent current myocardial inflammation and injury. A recent report incontestible that ST-elevation infarction (STEMI) activation is down 38th within the united states with

growing concern that patients don't obtain immediate medical attention due to fear of exposure to COVID-19 resulting in missed events [6].

It recommend in all patients concernedly for ACS, non-enteric coated aspirin 162–325 mg ought to lean right away if no contraindication exists followed by daily low dose aspirin (81 mg) indefinitely. P2Y12 substance (clopidogrel, ticagrelor, or prasugrel) ought to be considered in these patients with guidance from medicine with a length of medical aid for one year in most patients. For patients on medical aid before ACS, triple therapy ought to be used for the shortest length possible. A regimen of an instantaneous oral medicine (DOAC) with clopidogrel with short duration of aspirin is currently considered the quality of care and triple therapy with anticoagulant medication ought to be avoided.

Method

In this irregular, controlled, open-label, platform trial, many possible treatments were compared with usual care in patients hospitalised with COVID-19. The trial took place at 177 hospitals within the United Kingdom, 2 hospitals in state, and 2 hospitals in Nepal. Eligible and willing adults were randomly allotted in an exceedingly 1:1 ratio to either usual normal of care and 150 mg aspirin once per day till discharge or usual normal of care alone using web-based easy (unstratified) randomisation with allocation concealment. The first outcome was 28 day mortality. All analyses were done by intention to treat. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936) [5-6].

Table 1: Medication investigated for covid-19 positive patient [1]

Medication	Mechanism	Rivaroxaban
Lopinavir/Ritonavir	CYP3A4 inhibition/ P-glycoprotein competition	Do not co-administer
Tocilizumab	CYP3A4 inducer (weak)	No dose adjustment recommended
Sarilumab	CYP3A4 inducer	No dose adjustment recommended

Patients with moderate to severe COVID-19 present a very high risk of thromboembolic illness. This multicenter, prospective, randomized, event-driven study evaluates rivaroxaban compared with normal of care together with low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) at prophylactic doses if applicable within the interference of the composite of blood vessel occlusion (deep vein occlusion and/or fatal or non-fatal pulmonic embolism), blood vessel occlusion, new infarction, non-hemorrhagic stroke, all-cause mortality or progression to introduction and invasive ventilation 35 days post randomisation in patients with moderate to severe COVID-19 [4].

Duration of intervention per patient:

The total duration of the study treatment is versatile. For out-patients seven days of therapeutic medical aid are going to be among 28 days-phase of prophylactic medical aid, summing up to 35 days. For subjects that need hospitalization, the length of therapeutic medical aid are going to be a minimum of seven days or prolonged till discharge if hospitalized for quite 7 days post randomisation [7].

After discharge from the hospital the topic receives 28 days of thromboprophylaxis with rivaroxaban. No study medication is going to be given past day 60 post randomisation. This adds up to check length between 35 and 60 days depending on the length of the hospital keep.

Rivaroxaban has been approved for multiple indications worldwide. Over 100,000 subjects are studied from phase 1 through multiple massive part four studies in multiple settings, e.g. for the reduction within the risk of stroke and general embolism in arterial fibrillation, deep vein occlusion and embolism, major vessel events. The drug had not been studied in patients with COVID-19 as an anticoagulant agent, yet.

Antithrombotic recommendations for secondary prevention of stroke in the suspected or positive COVID-19 patient are currently unchanged from the general population assuming the absence of coagulopathy and prothrombotic state. For ischemic stroke due to small and large vessel atherosclerotic disease as well as embolic strokes of undetermined source, antiplatelet therapy with aspirin, clopidogrel, or aspirin/dipyridamole remains the appropriate first-line therapy. Dual antiplatelet therapy should be reserved for symptomatic intracranial atherosclerotic disease, certain carotid cases, recent stenting, and patients with recent minor stroke or high-risk TIA [8].

Conclusions

COVID-19 has challenged our considering the management of critically ill patients. The mechanisms of this malady and its complications' still are elucidated. That being said the principles of managing these patients are engineered on the foundations of evidence-based drugs in severely sick patients. There's a narrow therapeutic index between prevention and treatment of blood vessel and blood vessel occlusion in these patients and therefore the risk of bleeding. This document will be accustomed facilitate guide suppliers to treat cardiovascular patients at high risk throughout this pandemic. only by adhering to the principles of active what it all know and maintaining openness to what It don't will It get up to the best challenge of our professional lives.

Acknowledgements

Authors are thankful to the management of Geetanjali Institute of Pharmacy for providing necessary facilities.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

[1]. Watson, R. A., Johnson, D. M., Dharia, R. N., Merli, G. J., & Doherty, J. U. (2020). Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. Hospital practice (1995), 48(4), 169–179.

[2]. Jiménez, D., García-Sanchez, A., Rali, P., Muriel, A., Bikdeli, B., Ruiz-Artacho, P., ... & Monreal, M. (2021). Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Chest, 159(3), 1182-1196.

[3]. Kunutsor, S. K., & Laukkanen, J. A. (2020). Incidence of venous and arterial thromboembolic complications in COVID-19: a systematic review and meta-analysis. Thrombosis research, 196, 27-30.

[4]. Klok, F. A., Kruip, M. J. H. A., Van der Meer, N. J. M., Arbous, M. S., Gommers, D. A. M. P. J., Kant, K. M., ... & Endeman, H. (2020). Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thrombosis research, 191, 148-150.

[5]. Klok, F. A., Kruip, M. J. H. A., Van der Meer, N. J. M., Arbous, M. S., Gommers, D. A. M. P. J., Kant, K. M., ... & Endeman, H. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis research, 191, 145-147.

[6]. Smilowitz, N. R., Subashchandran, V., Yuriditsky, E., Horowitz, J. M., Reynolds, H. R., Hochman, J. S., & Berger, J. S. (2021). Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19. American Heart Journal, 231, 93-95.

[7]. Carestia, A., Davis, R. P., Grosjean, H., Lau, M. W., & Jenne, C. N. (2020). Acetylsalicylic acid inhibits intravascular coagulation during Staphylococcus aureus–induced sepsis in mice. Blood, 135(15), 1281-1286.

[8]. Antithrombotic Trialists' Collaboration. (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj, 324(7329), 71-86.

[9]. World health Organization. Coronavirus Disease. (COVID-19) situation report - 116. 2019. [cited 2020 May 15]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200515-covid-19-sitrep-116.pdf

[10]. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64:e139–228.

[11]. Fiedler, K. A., Maeng, M., Mehilli, J., Schulz-Schüpke, S., Byrne, R. A., Sibbing, D., & Sarafoff, N. (2015). Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. Journal of the American College of Cardiology, 65(16), 1619-1629.

[12]. Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., & Huang, C. (2020). Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA cardiology, 5(7), 802-810.